# CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

> **NCT00045682** · PHASE2 · COMPLETED · sponsor: **Gynecologic Oncology Group** · enrollment: 78 (actual)

## Conditions studied

- Primary Peritoneal Carcinoma
- Recurrent Ovarian Carcinoma

## Interventions

- **DRUG:** Paclitaxel Poliglumex

## Key facts

- **NCT ID:** NCT00045682
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2006-07-15
- **Final completion:** —
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2017-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00045682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00045682, "CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00045682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*